Belzutifan is this new kind of inhibitor that targets something called HIF-2α. It works by messing with these pathways that HIF-2α uses, which are key for cancer growth, especially RCC. This inhibitor is made for folks with RCC that’s linked to something called VHL syndrome.
You can get it as these tablets, each one’s 40 mg. The usual dose is 120 mg, and you take it just once a day. Each bottle has 90 tablets, so it’s good for a 30-day supply if you follow the dose they tell you to.
